Reactive oxygen species as a risk factor in verotoxin-1-exposed rats.
It has been suggested the the interaction of Escherichia coli O157-derived verotoxins (VTs) with the vascular endothelium plays a central role in the pathogenesis of the thrombotic microangiopathy and ischemic lesions characteristic of hemolytic uremic syndrome (HUS) and E. coli O157-associated hemorrhagic colitis. Intravenous administration of both E. coli O157-derived VT1 and lipopolysaccharide (LPS) in the rat induced a synergistic increase in thiobarbituric acid (TBA) values in those animal's plasma, as compared with that injected with VT1 or LPS alone. We then hypothesized that an increase in lipid peroxidation in the rat plasma was due to an enhanced production of endothelial cell-derived reactive oxidant. Based on determination of rat sera and cultured human aortic endothelial cells (HAECs), VT1 had little if any effect on LPS-stimulated increase of nitric oxide and the resultant peroxynitrite generations. Both RT-PCR and Western blot studies of reactive oxygen species-related enzymes showed that VT1 markedly decreased the expression of catalase mRNA and protein in HAECs, but caused less alteration in the levels of Cu, Zn-superoxide dismutase, and NADPH oxidase mRNA. Further studies by spin trapping analysis using 5, 5-dimethyl-1-pyrroline-N-oxide (DMPO) revealed a time-dependent increase in hydroxyl radicals by VT1 in HAECs. The accumulated data thus suggest that bacterial VT1 reduces mainly catalase levels in endothelial cells, which is synergistically potentiated by LPS, and that the resulting hydroxyl radical participates in endothelium injury through a marked enhancement of lipid peroxidation, leading to HUS.
First Department of Biochemistry, Saitama Medical School, 38 Morohongo Moroyama, Iruma-gun, Saitama, 350-0495, Japan. t_matsu@saitama-med.ac.jp
T
T
Matsunaga
T
T
Nakajima
M
M
Sonoda
S
S
Kawai
J
J
Kobayashi
I
I
Inoue
A
A
Satomi
S
S
Katayama
A
A
Hara
S
S
Hokari
T
T
Honda
T
T
Komoda
D000818:Animals; D001011:Aorta; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000633:toxicity*; D002374:Catalase / Q000235:genetics / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D019453:Escherichia coli O157; D006463:Hemolytic-Uremic Syndrome / Q000378:metabolism; D006801:Humans; D017665:Hydroxyl Radical / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D009566:Nitrates / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D010088:Oxidoreductases / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D012307:Risk Factors; D022622:Shiga Toxin 1; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D001427:Bacterial Toxins; D008070:Lipopolysaccharides; D009566:Nitrates; D012333:RNA, Messenger; D017382:Reactive Oxygen Species; D022622:Shiga Toxin 1; D017392:Thiobarbituric Acid Reactive Substances; C039642:peroxynitric acid; D009569:Nitric Oxide; D017665:Hydroxyl Radical; D010088:Oxidoreductases; D002374:Catalase